L. M. Semenyuk
L. M. Semenyuk has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Tetyana Yuzvenko
Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
12 shared publications Т. Ю. Юзвенко
Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ
10 shared publications- Ye. S. Kozachuk
Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ
9 shared publications - O. I. Kryzhanovska
Institute of Postgraduate Education, Bogomolets National Medical University, Kyiv, Ukraine
6 shared publications L. S. Chernukha
Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ
4 shared publicationsО. І. Крижановська
КНП «Київський міський пологовий будинок №5», Київ
4 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 64-69
Sarcopenia as an underrecognized complication of androgen insufficiency in women. Review
This review focuses on sarcopenia as an unaccounted complication of androgen insufficiency in women. The results of scientific studies, clinical trials, narrative and systematic reviews, as well as meta-analyses in the PubMed/Medline, Scopus, Web of Science and Google Scholar databases on sarcopenia and androgen insufficiency in women were analyzed. Perspectives on skeletal muscle have changed significantly in recent years. It has been proven that skeletal muscle is now recognized as a metabolically active endocrine organ that actively participate in the regulation of metabolic processes in many organs and tissues. Muscle contraction leads to biomechanical responses with the release of anti-inflammatory cytokines. Sarcopenia is considered as a progressive age-related decline in skeletal muscle mass and function. This process is associated with an increased risk of disability, falls, and metabolic disorders. Epidemiological studies confirm that women with androgen insufficiency, in addition to chronic complications, also experience muscle loss. Sarcopenia is officially recognized as a disease in the International Classification of Diseases (ICD-10: M62). Imbalance between hormones and myokines contributes to the development of sarcopenia, deterioration of carbohydrate metabolism and increased insulin resistance. Diagnostic criteria for sarcopenia include reduced muscle strength, mass, function, and quality. A stress-related factor in the development of sarcopenia in comorbid conditions has been identified. Obesity and sarcopenia share common pathophysiological characteristics, including insulin resistance, inflammation, hormonal changes, lack of physical activity, and oxidative stress. Evaluating the risk factors for sarcopenia, researchers note that chronic hypersecretion of cortisol contributes to muscle catabolism and may promote the development of sarcopenia. The review summarizes current data on the role of androgen insufficiency in the pathogenesis of sarcopenia, and outlines potential mechanisms of interaction and promising directions for therapeutic intervention.
- 30 March 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 64-69
Open AccessSarcopenia as an underrecognized complication of androgen insufficiency in women. Review
This review focuses on sarcopenia as an unaccounted complication of androgen insufficiency in women. The results of scientific studies, clinical trials, narrative and systematic reviews, as well as meta-analyses in the PubMed/Medline, Scopus, Web of Science and Google Scholar databases on sarcopenia and androgen insufficiency in women were analyzed. Perspectives on skeletal muscle have changed significantly in recent years. It has been proven that skeletal muscle is now recognized as a metabolically active endocrine organ that actively participate in the regulation of metabolic processes in many organs and tissues. Muscle contraction leads to biomechanical responses with the release of anti-inflammatory cytokines. Sarcopenia is considered as a progressive age-related decline in skeletal muscle mass and function. This process is associated with an increased risk of disability, falls, and metabolic disorders. Epidemiological studies confirm that women with androgen insufficiency, in addition to chronic complications, also experience muscle loss. Sarcopenia is officially recognized as a disease in the International Classification of Diseases (ICD-10: M62). Imbalance between hormones and myokines contributes to the development of sarcopenia, deterioration of carbohydrate metabolism and increased insulin resistance. Diagnostic criteria for sarcopenia include reduced muscle strength, mass, function, and quality. A stress-related factor in the development of sarcopenia in comorbid conditions has been identified. Obesity and sarcopenia share common pathophysiological characteristics, including insulin resistance, inflammation, hormonal changes, lack of physical activity, and oxidative stress. Evaluating the risk factors for sarcopenia, researchers note that chronic hypersecretion of cortisol contributes to muscle catabolism and may promote the development of sarcopenia. The review summarizes current data on the role of androgen insufficiency in the pathogenesis of sarcopenia, and outlines potential mechanisms of interaction and promising directions for therapeutic intervention.
- Open Access
- 30 September 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 63-72
Альтернативні підходи в лікуванні ендометріозу. Огляд літератури
Ендометріоз — це хронічне захворювання з багатьма виявами, основними з яких є біль і безпліддя. Захворювання зумовлене появою ендометрійподібних груп клітин, що складаються з ендометріоїдних залозистих клітин та/або стромальних клітин поза порожниною матки. Доведено, що тканина ендометрію, яка мігрує, виробляє естроген, взаємодіє з ендокринною, опорно‑руховою, судинною, репродуктивною та нервовою системами організму, що призводить до симптомів ендометріозу різної виразності, та трапляється в жінок будь‑якого віку. Складність лікування цього захворювання зумовлена хронічним перебігом і частим рецидуванням після хірургічного видалення. Тому існує нагальна потреба в розробці альтернативних або додаткових методів лікування ендометріозу з тривалими протирецидивними властивостями та мінімальною кількістю побічних ефектів за тривалого використання. Основними альтернативними підходами в лікуванні ендометріозу є заходи, що зменшують вплив оксидантного стресу, дають змогу усунути запальний процес, відновити гормонально‑імунний баланс в організмі жінки, впливають на проангіогенні й епігенетичні складові захворювання. Для цього використовують засоби відновлення кишкової мікробіоти, дієту з низьким вмістом олігосахаридів, дисахаридів, моносахаридів і поліолів, препарати рослинної дії, амінокислоти, комбіновані добавки мікроелементів, фізіотерапевтичні методики впливу на больовий синдром. Висновки. Харчові добавки мають позитивний вплив при лікуванні ендометріозу. Деякі з них можна застосовувати як додаткове лікування симптомів жіночої сексуальної дисфункції. Лікування має бути персоніфікованим з урахуванням репродуктивних планів жінок, віку діагностування ендометріозу, форми та стадії захворювання, супутньої патології (ендокринно‑імунні розлади). Використання рослинних препаратів потребує дослідження, зокрема їхнього впливу на рівні центральних гормонів гіпофіза.
- 30 September 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 63-72
Open AccessАльтернативні підходи в лікуванні ендометріозу. Огляд літератури
Ендометріоз — це хронічне захворювання з багатьма виявами, основними з яких є біль і безпліддя. Захворювання зумовлене появою ендометрійподібних груп клітин, що складаються з ендометріоїдних залозистих клітин та/або стромальних клітин поза порожниною матки. Доведено, що тканина ендометрію, яка мігрує, виробляє естроген, взаємодіє з ендокринною, опорно‑руховою, судинною, репродуктивною та нервовою системами організму, що призводить до симптомів ендометріозу різної виразності, та трапляється в жінок будь‑якого віку. Складність лікування цього захворювання зумовлена хронічним перебігом і частим рецидуванням після хірургічного видалення. Тому існує нагальна потреба в розробці альтернативних або додаткових методів лікування ендометріозу з тривалими протирецидивними властивостями та мінімальною кількістю побічних ефектів за тривалого використання. Основними альтернативними підходами в лікуванні ендометріозу є заходи, що зменшують вплив оксидантного стресу, дають змогу усунути запальний процес, відновити гормонально‑імунний баланс в організмі жінки, впливають на проангіогенні й епігенетичні складові захворювання. Для цього використовують засоби відновлення кишкової мікробіоти, дієту з низьким вмістом олігосахаридів, дисахаридів, моносахаридів і поліолів, препарати рослинної дії, амінокислоти, комбіновані добавки мікроелементів, фізіотерапевтичні методики впливу на больовий синдром. Висновки. Харчові добавки мають позитивний вплив при лікуванні ендометріозу. Деякі з них можна застосовувати як додаткове лікування симптомів жіночої сексуальної дисфункції. Лікування має бути персоніфікованим з урахуванням репродуктивних планів жінок, віку діагностування ендометріозу, форми та стадії захворювання, супутньої патології (ендокринно‑імунні розлади). Використання рослинних препаратів потребує дослідження, зокрема їхнього впливу на рівні центральних гормонів гіпофіза.
- Open Access
- 30 June 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 13-19
Autoimmune thyroid diseases and their impact on sexual and reproductive function in young women
Objective — to determine the relationship between the characteristics of the hormonal background and signs of FSD in women with ATD in the prediction of the success of future gestation and the formation of POF. Materials and methods. The study design is a prospective study that included 30 women of reproductive age (main group) with ATD and 30 healthy women of reproductive age — the control group. The levels of steroid and peptide hormones, domains of FSD and the ovulatory phase of the menstrual cycle were studied during 9 months of therapy. The presence of female sexual dysfunction was determined using a questionnaire with scoring on an online calculator. The treatment included the use of a complex of herbal remedies recommended for hypoandrogenic ovarian dysfunction. Statistical analysis was performed using the specialized statistical software package SPSS 25.0 (StatSoft Inc., USA). Results. All women in the main group had a combination of signs of FSD with anovulation against the background of clinically significant TPOAb indicators. Correlations were established: statistically significant relationship between desire and 17-OP indicators; arousal and progesterone; orgasm and TPOAb, TSH, progesterone; pain and homocysteine, TSH; FSFI and TSH, between questionnaire scores and hormonal indicators: orgasm and vitamin D; AMH and pleasure, pain, FSFI (p<0.05). After 9 months of therapy, 60.0% (n=18) of the patients in the main group had persistent DHEA-S deficiency. Monitoring of ovulation by ultrasound folliculometry in the main group indicated a negative prognosis for natural pregnancy in 16 (53.3%) of the examined. Conclusions. Familiarity of doctors of related specialties with the problem of autoimmune thyroid pathology and its consequences for the sexual and reproductive health of women can improve their awareness of the individualized prognosis of pregnancy. Pregnancy planning in women with ATD with an emphasis on their age and the value of thyroid antibody titers. Determination of reproductive steroidogenesis along with examination of the thyroid panel. With low DHEA-S indicators — indications for examination of adrenal function.
- 30 June 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 13-19
Open AccessAutoimmune thyroid diseases and their impact on sexual and reproductive function in young women
Objective — to determine the relationship between the characteristics of the hormonal background and signs of FSD in women with ATD in the prediction of the success of future gestation and the formation of POF. Materials and methods. The study design is a prospective study that included 30 women of reproductive age (main group) with ATD and 30 healthy women of reproductive age — the control group. The levels of steroid and peptide hormones, domains of FSD and the ovulatory phase of the menstrual cycle were studied during 9 months of therapy. The presence of female sexual dysfunction was determined using a questionnaire with scoring on an online calculator. The treatment included the use of a complex of herbal remedies recommended for hypoandrogenic ovarian dysfunction. Statistical analysis was performed using the specialized statistical software package SPSS 25.0 (StatSoft Inc., USA). Results. All women in the main group had a combination of signs of FSD with anovulation against the background of clinically significant TPOAb indicators. Correlations were established: statistically significant relationship between desire and 17-OP indicators; arousal and progesterone; orgasm and TPOAb, TSH, progesterone; pain and homocysteine, TSH; FSFI and TSH, between questionnaire scores and hormonal indicators: orgasm and vitamin D; AMH and pleasure, pain, FSFI (p<0.05). After 9 months of therapy, 60.0% (n=18) of the patients in the main group had persistent DHEA-S deficiency. Monitoring of ovulation by ultrasound folliculometry in the main group indicated a negative prognosis for natural pregnancy in 16 (53.3%) of the examined. Conclusions. Familiarity of doctors of related specialties with the problem of autoimmune thyroid pathology and its consequences for the sexual and reproductive health of women can improve their awareness of the individualized prognosis of pregnancy. Pregnancy planning in women with ATD with an emphasis on their age and the value of thyroid antibody titers. Determination of reproductive steroidogenesis along with examination of the thyroid panel. With low DHEA-S indicators — indications for examination of adrenal function.
- Open Access
- 22 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (3) , 306-313
Determining the relationship between hormonal background characteristics and signs of female sexual dysfunction in women with and without endometriosis in the prediction of gestational success
Background. Overcoming infertility in young women is recognized as one of the most important tasks of modern medicine. Among the factors that reduce female fertility, endometriosis remains relevant. The widespread prevalence of diseases with common pathogenetic factors has led to the emergence of diseases of “old age” in women of reproductive age. These include, in particular, female sexual dysfunction (FSD). The relationship between FSD and hormonal indicators as prognostic factors of female reproductive health has been little studied to date. The purpose was to determine the relationship between the characteristics of the hormonal background and signs of FSD in women with and without endometriosis in the prediction of the success of future gestation. Materials and methods. The study design is a prospective cohort study, which included 130 women of reproductive age. They were divided into 3 groups: group IA (n = 70) — a combination of female sexual dysfunction and extragenital endometriosis, the comparison group IB (n = 30) — female sexual dysfunction without extragenital endometriosis, the control group II (n = 30) — healthy reproductively active women. The end points of the study were levels of pituitary and ovarian hormones, proandrogenic steroids, ovulatory menstrual cycles. These indicators were studied before treatment and at the control periods of therapy — 3, 6, 9 months. The presence of FSD was determined using a questionnaire with scoring on an online calculator, when the female sexual function index was less than 26.55 points. The therapy was aimed at restoring the correct functioning of ovarian steroidogenesis using herbal therapy. Statistical analysis was performed using a specialized statistical software package SPSS 25.0 (StatSoft Inc., USA). Results. A significant normalization of pituitary peptide hormones in the comparison groups occurred in the period from the sixth to the ninth month of therapy. As for the estradiol level, its significant increase was noted in both comparison groups throughout the entire observation period. At the ninth month, the values of progesterone in patients with FSD and endometriosis were significantly higher in than those without it (p = 0.002). Despite the treatment, the estradiol and progesterone levels in the IA group remained significantly lower than in the control group throughout the entire observation period (p < 0.001). In patients without endometriosis (IB group), after 9 months of treatment, only estrogen values were successfully corrected, which were comparable to the control group. Analysis using Dunn’s test with Bonferroni correction showed no statistically significant difference between the IA and IV groups throughout the entire course of treatment (p > 0.05). Correlation analysis revealed that in patients with FSD and endometriosis after 6 months of treatment, changes in the studied hormones statistically significantly correlated with improvements in scores in all domains of the questionnaire. At the control period of 6 months, 20 (66.3 %) women were not ready for safe conception. In the 9-month control period, 16 (53.3 %) patients in this group were not ready for safe motherhood. Conclusions. Women with external-internal endometriosis and FSD and women with FSD alone have different pathogenetic background in the formation of gestational pathology. Therapy of patients with any form of FSD should be personalized. Assessment of FSD domains allows for rapid diagnosis of future gestational risks in women of reproductive age.
- 22 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (3) , 306-313
Open AccessDetermining the relationship between hormonal background characteristics and signs of female sexual dysfunction in women with and without endometriosis in the prediction of gestational success
Background. Overcoming infertility in young women is recognized as one of the most important tasks of modern medicine. Among the factors that reduce female fertility, endometriosis remains relevant. The widespread prevalence of diseases with common pathogenetic factors has led to the emergence of diseases of “old age” in women of reproductive age. These include, in particular, female sexual dysfunction (FSD). The relationship between FSD and hormonal indicators as prognostic factors of female reproductive health has been little studied to date. The purpose was to determine the relationship between the characteristics of the hormonal background and signs of FSD in women with and without endometriosis in the prediction of the success of future gestation. Materials and methods. The study design is a prospective cohort study, which included 130 women of reproductive age. They were divided into 3 groups: group IA (n = 70) — a combination of female sexual dysfunction and extragenital endometriosis, the comparison group IB (n = 30) — female sexual dysfunction without extragenital endometriosis, the control group II (n = 30) — healthy reproductively active women. The end points of the study were levels of pituitary and ovarian hormones, proandrogenic steroids, ovulatory menstrual cycles. These indicators were studied before treatment and at the control periods of therapy — 3, 6, 9 months. The presence of FSD was determined using a questionnaire with scoring on an online calculator, when the female sexual function index was less than 26.55 points. The therapy was aimed at restoring the correct functioning of ovarian steroidogenesis using herbal therapy. Statistical analysis was performed using a specialized statistical software package SPSS 25.0 (StatSoft Inc., USA). Results. A significant normalization of pituitary peptide hormones in the comparison groups occurred in the period from the sixth to the ninth month of therapy. As for the estradiol level, its significant increase was noted in both comparison groups throughout the entire observation period. At the ninth month, the values of progesterone in patients with FSD and endometriosis were significantly higher in than those without it (p = 0.002). Despite the treatment, the estradiol and progesterone levels in the IA group remained significantly lower than in the control group throughout the entire observation period (p < 0.001). In patients without endometriosis (IB group), after 9 months of treatment, only estrogen values were successfully corrected, which were comparable to the control group. Analysis using Dunn’s test with Bonferroni correction showed no statistically significant difference between the IA and IV groups throughout the entire course of treatment (p > 0.05). Correlation analysis revealed that in patients with FSD and endometriosis after 6 months of treatment, changes in the studied hormones statistically significantly correlated with improvements in scores in all domains of the questionnaire. At the control period of 6 months, 20 (66.3 %) women were not ready for safe conception. In the 9-month control period, 16 (53.3 %) patients in this group were not ready for safe motherhood. Conclusions. Women with external-internal endometriosis and FSD and women with FSD alone have different pathogenetic background in the formation of gestational pathology. Therapy of patients with any form of FSD should be personalized. Assessment of FSD domains allows for rapid diagnosis of future gestational risks in women of reproductive age.
- Open Access
- 31 March 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 13-21
Management of vitamin D deficiency and hypothyroidism in pre-pregnancy preparation of women with sexual dysfunction associated with endometriosis
In modern conditions, infertile women have a high percentage of so‑called «diseases of civilization»: autoimmune thyroid disorders, dysmetabolic processes, endometriosis, and female sexual dysfunction. Researchers note the role of vitamin D deficiency or insufficiency in the manifestations of these pathological conditions. The lack of an integrated assessment of health and a clear personalized approach when prescribing treatment gives the pathological process a chronic nature and sometimes leads to a persistent loss of fertility. Objective — to determine the relationship between the features of FSD in women with and without endometriosis and changes in hormonal support of reproductive function during the control periods of therapy. Materials and methods. Study design — prospective cohort study, which included 130 women of reproductive age. Patients were stratified into 3 groups according to diagnosed female sexual dysfunction and external genital endometriosis: Group IA (n=70) — main group — women with a combination of female sexual dysfunction and external genital endometriosis; Group IB (n=30) — comparison group — women with female sexual dysfunction without external genital endometriosis; Group II (n=30) — control group — healthy reproductively active women. Management of low vitamin D levels and thyroid hypofunction was carried out as part of complex therapy for hormonal homeostasis disorders. The study endpoints were: 1. Vitamin D levels, Thyroid peroxidase (TPO) antibody (TPO‑Ab) levels, Thyroid stimulating hormone (TSH) levels, FSD. The indicated indicators were studied before treatment and at the control periods of therapy — 3, 6, 9 months. Biochemical studies were conducted in the clinical laboratory of biochemical, hormonal and immunological studies of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine. Female sexual dysfunction was assessed using a validated questionnaire with scoring conducted via an online calculator. The presence of FSD was determined when the value of the female sexual function index (FSFI) was less than 26.55 points. Statistical analysis was performed using the specialized statistical software package SPSS 25.0 (StatSoft Inc., USA). Results. In women with FSD, regardless of the presence of endometriosis, a statistically significant increase in vitamin D was achieved 3 months after the start of therapy, with positive dynamics maintained until the 9th month, p<0.001. In the comparison groups, changes in the thyroid hormone profile were noted at these times: a statistically significant decrease in the average values of TPO‑Ab after 3 months (p<0.001) and TSH after 6 months from the start of treatment (p<0.001). Regarding TSH values, a statistically significant difference was observed between patients in groups IA and IB at the 6‑month and 9‑month marks, with levels being higher in IA (p=0.006 and p=0.018, respectively). These laboratory parameters were statistically significantly higher in women with FSD compared to the control group throughout the entire observation period, p0.05. However, in women who persisted FSD, vitamin D deficiency was significantly more often detected (p<0.05). Using binary logistic regression, it was found that only the maintenance of functionally elevated TSH levels was a predictive factor for the maintenance of FSD in this cohort of patients. Linear regression analysis showed that in patients with endometriosis, only increased vitamin D levels significantly improved scores in all categories of the FSD questionnaire. Conclusions. Combined correction of vitamin D and TSH levels allows to achieve a positive therapeutic effect in women with both endometriosis and monoform. Reducing TSH levels in women with and without endometriosis significantly affects the frequency of detection of VSD against the background of treatment and improves its manifestations in the categories of «Desire», «Lubrication», «Orgasm» and «Pain» in patients without endometriosis. Therefore, the preservation of functionally elevated TSH levels is a prognostic factor for the preservation of FSD in women. Endometriosis worsens the response of the woman’s body to the prescribed treatment, which requires individualized medical tactics at the pre‑gravid stage.
- 31 March 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 13-21
Open AccessManagement of vitamin D deficiency and hypothyroidism in pre-pregnancy preparation of women with sexual dysfunction associated with endometriosis
In modern conditions, infertile women have a high percentage of so‑called «diseases of civilization»: autoimmune thyroid disorders, dysmetabolic processes, endometriosis, and female sexual dysfunction. Researchers note the role of vitamin D deficiency or insufficiency in the manifestations of these pathological conditions. The lack of an integrated assessment of health and a clear personalized approach when prescribing treatment gives the pathological process a chronic nature and sometimes leads to a persistent loss of fertility. Objective — to determine the relationship between the features of FSD in women with and without endometriosis and changes in hormonal support of reproductive function during the control periods of therapy. Materials and methods. Study design — prospective cohort study, which included 130 women of reproductive age. Patients were stratified into 3 groups according to diagnosed female sexual dysfunction and external genital endometriosis: Group IA (n=70) — main group — women with a combination of female sexual dysfunction and external genital endometriosis; Group IB (n=30) — comparison group — women with female sexual dysfunction without external genital endometriosis; Group II (n=30) — control group — healthy reproductively active women. Management of low vitamin D levels and thyroid hypofunction was carried out as part of complex therapy for hormonal homeostasis disorders. The study endpoints were: 1. Vitamin D levels, Thyroid peroxidase (TPO) antibody (TPO‑Ab) levels, Thyroid stimulating hormone (TSH) levels, FSD. The indicated indicators were studied before treatment and at the control periods of therapy — 3, 6, 9 months. Biochemical studies were conducted in the clinical laboratory of biochemical, hormonal and immunological studies of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine. Female sexual dysfunction was assessed using a validated questionnaire with scoring conducted via an online calculator. The presence of FSD was determined when the value of the female sexual function index (FSFI) was less than 26.55 points. Statistical analysis was performed using the specialized statistical software package SPSS 25.0 (StatSoft Inc., USA). Results. In women with FSD, regardless of the presence of endometriosis, a statistically significant increase in vitamin D was achieved 3 months after the start of therapy, with positive dynamics maintained until the 9th month, p<0.001. In the comparison groups, changes in the thyroid hormone profile were noted at these times: a statistically significant decrease in the average values of TPO‑Ab after 3 months (p<0.001) and TSH after 6 months from the start of treatment (p<0.001). Regarding TSH values, a statistically significant difference was observed between patients in groups IA and IB at the 6‑month and 9‑month marks, with levels being higher in IA (p=0.006 and p=0.018, respectively). These laboratory parameters were statistically significantly higher in women with FSD compared to the control group throughout the entire observation period, p0.05. However, in women who persisted FSD, vitamin D deficiency was significantly more often detected (p<0.05). Using binary logistic regression, it was found that only the maintenance of functionally elevated TSH levels was a predictive factor for the maintenance of FSD in this cohort of patients. Linear regression analysis showed that in patients with endometriosis, only increased vitamin D levels significantly improved scores in all categories of the FSD questionnaire. Conclusions. Combined correction of vitamin D and TSH levels allows to achieve a positive therapeutic effect in women with both endometriosis and monoform. Reducing TSH levels in women with and without endometriosis significantly affects the frequency of detection of VSD against the background of treatment and improves its manifestations in the categories of «Desire», «Lubrication», «Orgasm» and «Pain» in patients without endometriosis. Therefore, the preservation of functionally elevated TSH levels is a prognostic factor for the preservation of FSD in women. Endometriosis worsens the response of the woman’s body to the prescribed treatment, which requires individualized medical tactics at the pre‑gravid stage.
- Open Access
- 31 December 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 51-56
Individualized approach in the management of women with female sexual dysfunction, external genital endometriosis and hyperhomocysteinemia
The problem of treatment of endometriosis in women of reproductive age remains an urgent task for obstetricians and gynecologists, as it has a direct impact on women’s ability to conceive. Overcoming the demographic crisis in Ukraine requires doctors to find new methods and techniques in a personalized approach to the treatment of women with endometriosis. The presence of comorbid pathology in endometriosis, in particular hyperhomocysteinemia (HHC) and female sexual dysfunction (FSD), necessitates individualization of the management of such patients. Objective — to determine the effect of surgical treatment of women with external‑intraoral endometriosis and female sexual dysfunction and hyperhomocysteinemia on the characteristics of their hormonal homeostasis and indicators of FSD. Materials and methods. The study included 19 patients with external‑intrinsic endometriosis and female sexual dysfunction and hyperhomocysteinemia with homozygous form of MTRF gene polymorphism. Surgical intervention in the form of laparoscopic cystectomy was performed in 12 patients (group I). 7 patients refused to undergo surgery (group II). Surgical intervention was performed 6 months after the start of treatment. The hormonal status and parameters of the FSD were studied according to the results of a questionnaire at the time of treatment, 6 months after the start of conservative therapy, and 3 months after surgery. Results. At 3 months after surgery, the values of vitamin D, FSH, LH, estradiol, progesterone, free T, DHEA‑S and 17‑OH were statistically significantly higher in women of group I compared with patients who did not undergo surgery — II (p<0.05), and the levels of homocysteine, TSH, prolactin were lower (p<0.05). In patients of group I, a statistically significant increase in questionnaire scores was noted after surgery compared with patients who did not undergo surgery at a significance level of p<0.001. Against the background of the total duration of treatment (6 months of conservative therapy + 3 months of combined treatment — conservative therapy + surgery) in patients of group I with a homozygous mutation, it was possible to achieve normalization of the FSD in all 12 (100.0%) patients. In patients who did not undergo surgery, no normalization of FSD was observed. Conclusions. The treatment of women with FSD and external genital endometriosis should be individualized, taking into account the entire clinical problem, including the impact of the disease and the impact of its treatment on the quality of life. Pregravidar preparation of women with LBP and BPH and hypoandrogenism in homozygous carriage of MTRF polymorphism genes should include surgical removal of ovarian endometrioma to improve LBP and hormonal background for pregnancy.
- 31 December 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 51-56
Open AccessIndividualized approach in the management of women with female sexual dysfunction, external genital endometriosis and hyperhomocysteinemia
The problem of treatment of endometriosis in women of reproductive age remains an urgent task for obstetricians and gynecologists, as it has a direct impact on women’s ability to conceive. Overcoming the demographic crisis in Ukraine requires doctors to find new methods and techniques in a personalized approach to the treatment of women with endometriosis. The presence of comorbid pathology in endometriosis, in particular hyperhomocysteinemia (HHC) and female sexual dysfunction (FSD), necessitates individualization of the management of such patients. Objective — to determine the effect of surgical treatment of women with external‑intraoral endometriosis and female sexual dysfunction and hyperhomocysteinemia on the characteristics of their hormonal homeostasis and indicators of FSD. Materials and methods. The study included 19 patients with external‑intrinsic endometriosis and female sexual dysfunction and hyperhomocysteinemia with homozygous form of MTRF gene polymorphism. Surgical intervention in the form of laparoscopic cystectomy was performed in 12 patients (group I). 7 patients refused to undergo surgery (group II). Surgical intervention was performed 6 months after the start of treatment. The hormonal status and parameters of the FSD were studied according to the results of a questionnaire at the time of treatment, 6 months after the start of conservative therapy, and 3 months after surgery. Results. At 3 months after surgery, the values of vitamin D, FSH, LH, estradiol, progesterone, free T, DHEA‑S and 17‑OH were statistically significantly higher in women of group I compared with patients who did not undergo surgery — II (p<0.05), and the levels of homocysteine, TSH, prolactin were lower (p<0.05). In patients of group I, a statistically significant increase in questionnaire scores was noted after surgery compared with patients who did not undergo surgery at a significance level of p<0.001. Against the background of the total duration of treatment (6 months of conservative therapy + 3 months of combined treatment — conservative therapy + surgery) in patients of group I with a homozygous mutation, it was possible to achieve normalization of the FSD in all 12 (100.0%) patients. In patients who did not undergo surgery, no normalization of FSD was observed. Conclusions. The treatment of women with FSD and external genital endometriosis should be individualized, taking into account the entire clinical problem, including the impact of the disease and the impact of its treatment on the quality of life. Pregravidar preparation of women with LBP and BPH and hypoandrogenism in homozygous carriage of MTRF polymorphism genes should include surgical removal of ovarian endometrioma to improve LBP and hormonal background for pregnancy.
- Open Access
- 30 September 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 23-27
Reduction in the level of dehydroepiandrosterone as an indicator of stress-associated reproductive health disorders. Review
The issue of changes in reproductive steroidogenesis in women of childbearing age arises from disruptions in the ovarian‑menstrual cycle and their consequences (e.g., infertility, miscarriage, premature delivery, decreased libido, and signs of sexual dysfunction). The war in Ukraine has exacerbated the existing demographic crisis, highlighting the strategic importance of reproduction for the country. Under the conditions of martial law, the stress level in the human body increases, leading to an increase in cortisol levels. The relationship between stress and increased cortisol levels and women’s reproductive function has been sufficiently studied. However, the problem of the correlation between stress, hypercortisolemia, and changes in the level of dehydroepiandrosterone (DHEA), as a precursor of steroidogenesis, and the reproductive function of women remains under active investigation. DHEA is considered a precursor to the production of sex hormones (testosterone, estrogen, progesterone), but it is also produced in greater amounts as a moderator of the stress response. Researchers studying the effects of DHEA on the human body note that the ratio of DHEA to cortisol has been associated with increased stress resistance: with DHEA levels higher than cortisol levels, stress resistance increases, and women experience fewer negative consequences from the same stressors compared to individuals with a lower DHEA/cortisol ratio. Researchers of menstrual function in teenagers have reached similar conclusions. When reviewing recent papers on the value of DHEA levels for ovarian reserve, we found numerous studies reporting improvements in IVF outcomes in women with low follicular reserves. It is to the works of reproductive scientists that we owe information about the positive role of pro‑androgenic steroids in improving fertility, especially in the context of using androgens in ovulation stimulation protocols. Taking into account all of the above, we consider the use of DHEA in the pre‑gravid stage to be promising for women with hypoandrogenism, stress‑related menstrual disorders, and functionally increased cortisol levels.
- 30 September 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 23-27
Open AccessReduction in the level of dehydroepiandrosterone as an indicator of stress-associated reproductive health disorders. Review
The issue of changes in reproductive steroidogenesis in women of childbearing age arises from disruptions in the ovarian‑menstrual cycle and their consequences (e.g., infertility, miscarriage, premature delivery, decreased libido, and signs of sexual dysfunction). The war in Ukraine has exacerbated the existing demographic crisis, highlighting the strategic importance of reproduction for the country. Under the conditions of martial law, the stress level in the human body increases, leading to an increase in cortisol levels. The relationship between stress and increased cortisol levels and women’s reproductive function has been sufficiently studied. However, the problem of the correlation between stress, hypercortisolemia, and changes in the level of dehydroepiandrosterone (DHEA), as a precursor of steroidogenesis, and the reproductive function of women remains under active investigation. DHEA is considered a precursor to the production of sex hormones (testosterone, estrogen, progesterone), but it is also produced in greater amounts as a moderator of the stress response. Researchers studying the effects of DHEA on the human body note that the ratio of DHEA to cortisol has been associated with increased stress resistance: with DHEA levels higher than cortisol levels, stress resistance increases, and women experience fewer negative consequences from the same stressors compared to individuals with a lower DHEA/cortisol ratio. Researchers of menstrual function in teenagers have reached similar conclusions. When reviewing recent papers on the value of DHEA levels for ovarian reserve, we found numerous studies reporting improvements in IVF outcomes in women with low follicular reserves. It is to the works of reproductive scientists that we owe information about the positive role of pro‑androgenic steroids in improving fertility, especially in the context of using androgens in ovulation stimulation protocols. Taking into account all of the above, we consider the use of DHEA in the pre‑gravid stage to be promising for women with hypoandrogenism, stress‑related menstrual disorders, and functionally increased cortisol levels.
- Open Access
- 31 May 2024
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Zaporozhye Medical Journal
- Vol. 26 (3) , 210-216
Physiological characteristics of reproductive-age patients with female sexual dysfunction and endometriosis (a comparison of clinical and laboratory parameters in different study groups)
Endometriosis is an estrogen-dependent inflammatory disease that affects 5–10 % of reproductive-age women. About two-thirds of women with endometriosis have sexual dysfunction caused by dyspareunia, which negatively affects the quality of life and mental health of a woman. The aim of the study is to identify differences in clinical and laboratory parameters in study groups of reproductive-age female patients with the aim of obtaining information about specifics of the female sexual dysfunction (FSD) development in women with endometriosis. Materials and methods. The examination results of the hormonal profile, sexual functional index and other laboratory markers were analyzed in 130 women of active reproductive age: Group I (n = 100) – the main group – women with manifestations of FSD including subgroup IA (n = 70) – women with FSD and external genital endometriosis and IB subgroup (n = 30) – women with FSD alone; Group II (n = 30) – healthy women. Results. Women with endometriosis combined with FSD (IA) exhibited a reproductive hormonal profile different from that in women with FSD (IB), which was seen by a significant difference in follicle-stimulating hormone (FSH), estradiol, free testosterone and dehydroepiandrosterone sulfate values (p = 0.001, p = 0.039, p = 0.035 and p = 0.035, respectively). Vitamin D deficiency and hyperhomocysteinemia, the presence of antibodies to thyroperoxidase and functional hyperprolactinemia have been detected in all the women with FSD signs, regardless of the concomitant endometriosis presence. Post-hoc analysis (Mann–Whitney test) has shown that the mean scores for all categories of the Female Sexual Function Index (FSFI) questionnaire were statistically significantly higher in Group IA patients compared to those in Group II patients (p < 0.001). Conclusions. The hormonal profile of women with endometriosis is characterized by increased levels of FSH, estradiol, free testosterone and dehydroepiandrosterone sulfate as compared to that in women with FSD alone, however it does not prevent the development of FSD signs in them and is accompanied by different indicators of the FSFI domains. Ендометріоз – естрогензалежне запальне захворювання, що уражає 5–10 % жінок репродуктивного віку. Майже дві третини жінок з ендометріозом мають сексуальну дисфункцію, що зумовлена диспареунією, негативно впливає на якість життя та психічне здоров’я. Мета роботи – визначити відмінності клініко-лабораторних показників у різних групах пацієнток репродуктивного віку для отримання інформації щодо особливостей формування підґрунтя розвитку жіночої сексуальної дисфункції (ЖСД) у хворих на ендометріоз. Матеріали і методи. Проаналізували результати обстеження гормонального фону, індексу сексуальної дисфункції (ІСД) та інших лабораторних маркерів 130 жінок активного репродуктивного віку. Обстежених поділили на групи: у І (n = 100) – основну групу – залучили жінок із ЖСД, з-поміж них розрізняли ІА підгрупу (n = 70) – жінки із ЖСД і зовнішнім генітальним ендометріозом і ІВ підгрупу (n = 30) – жінки тільки з ЖСД; у ІІ групу (n = 30) ввійшли здорові жінки. Результати. Гормональний репродуктивний фон жінок з ендометріозом, що поєднаний із ЖСД (група ІА), відрізняється від такого в пацієнток із моноформою ЖСД (група ІВ). Це виявили за достовірною різницею рівнів фолікулостимулювального гормона, естрадіолу, тестостерону вільного та дегідроепіандростерон-сульфату – р = 0,001, р = 0,039, р = 0,035 та р = 0,035 відповідно. У всіх жінок з ознаками ЖСД (незалежно від наявності супутнього ендометріозу) виявили недостатність вітаміну D, гіпергомоцистеїнемію, антитіла до тиреопероксидази, діагностували функціональну гіперпролактинемію. Апостеріорний аналіз (критерій Манна–Вітні) показав, що у пацієнток групи ІА середні значення балів за всіма категоріями анкети визначення ІСД статистично значущо вищі порівняно з параметрами обстежених із групи ІВ (р < 0,001). Висновки. Гормональний фон жінок із зовнішнім генітальним ендометріозом і ЖСД порівняно з пацієнтками з моноформою ЖСД характеризується підвищеними рівнями фолікулостимулювального гормона, естрадіолу, тестостерону вільного та дегідроепіандростерон-сульфату, при цьому не запобігає формуванню у них ознак ЖСД і супроводжується різними...
- 31 May 2024
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Zaporozhye Medical Journal
- Vol. 26 (3) , 210-216
Open AccessPhysiological characteristics of reproductive-age patients with female sexual dysfunction and endometriosis (a comparison of clinical and laboratory parameters in different study groups)
Endometriosis is an estrogen-dependent inflammatory disease that affects 5–10 % of reproductive-age women. About two-thirds of women with endometriosis have sexual dysfunction caused by dyspareunia, which negatively affects the quality of life and mental health of a woman. The aim of the study is to identify differences in clinical and laboratory parameters in study groups of reproductive-age female patients with the aim of obtaining information about specifics of the female sexual dysfunction (FSD) development in women with endometriosis. Materials and methods. The examination results of the hormonal profile, sexual functional index and other laboratory markers were analyzed in 130 women of active reproductive age: Group I (n = 100) – the main group – women with manifestations of FSD including subgroup IA (n = 70) – women with FSD and external genital endometriosis and IB subgroup (n = 30) – women with FSD alone; Group II (n = 30) – healthy women. Results. Women with endometriosis combined with FSD (IA) exhibited a reproductive hormonal profile different from that in women with FSD (IB), which was seen by a significant difference in follicle-stimulating hormone (FSH), estradiol, free testosterone and dehydroepiandrosterone sulfate values (p = 0.001, p = 0.039, p = 0.035 and p = 0.035, respectively). Vitamin D deficiency and hyperhomocysteinemia, the presence of antibodies to thyroperoxidase and functional hyperprolactinemia have been detected in all the women with FSD signs, regardless of the concomitant endometriosis presence. Post-hoc analysis (Mann–Whitney test) has shown that the mean scores for all categories of the Female Sexual Function Index (FSFI) questionnaire were statistically significantly higher in Group IA patients compared to those in Group II patients (p < 0.001). Conclusions. The hormonal profile of women with endometriosis is characterized by increased levels of FSH, estradiol, free testosterone and dehydroepiandrosterone sulfate as compared to that in women with FSD alone, however it does not prevent the development of FSD signs in them and is accompanied by different indicators of the FSFI domains. Ендометріоз – естрогензалежне запальне захворювання, що уражає 5–10 % жінок репродуктивного віку. Майже дві третини жінок з ендометріозом мають сексуальну дисфункцію, що зумовлена диспареунією, негативно впливає на якість життя та психічне здоров’я. Мета роботи – визначити відмінності клініко-лабораторних показників у різних групах пацієнток репродуктивного віку для отримання інформації щодо особливостей формування підґрунтя розвитку жіночої сексуальної дисфункції (ЖСД) у хворих на ендометріоз. Матеріали і методи. Проаналізували результати обстеження гормонального фону, індексу сексуальної дисфункції (ІСД) та інших лабораторних маркерів 130 жінок активного репродуктивного віку. Обстежених поділили на групи: у І (n = 100) – основну групу – залучили жінок із ЖСД, з-поміж них розрізняли ІА підгрупу (n = 70) – жінки із ЖСД і зовнішнім генітальним ендометріозом і ІВ підгрупу (n = 30) – жінки тільки з ЖСД; у ІІ групу (n = 30) ввійшли здорові жінки. Результати. Гормональний репродуктивний фон жінок з ендометріозом, що поєднаний із ЖСД (група ІА), відрізняється від такого в пацієнток із моноформою ЖСД (група ІВ). Це виявили за достовірною різницею рівнів фолікулостимулювального гормона, естрадіолу, тестостерону вільного та дегідроепіандростерон-сульфату – р = 0,001, р = 0,039, р = 0,035 та р = 0,035 відповідно. У всіх жінок з ознаками ЖСД (незалежно від наявності супутнього ендометріозу) виявили недостатність вітаміну D, гіпергомоцистеїнемію, антитіла до тиреопероксидази, діагностували функціональну гіперпролактинемію. Апостеріорний аналіз (критерій Манна–Вітні) показав, що у пацієнток групи ІА середні значення балів за всіма категоріями анкети визначення ІСД статистично значущо вищі порівняно з параметрами обстежених із групи ІВ (р < 0,001). Висновки. Гормональний фон жінок із зовнішнім генітальним ендометріозом і ЖСД порівняно з пацієнтками з моноформою ЖСД характеризується підвищеними рівнями фолікулостимулювального гормона, естрадіолу, тестостерону вільного та дегідроепіандростерон-сульфату, при цьому не запобігає формуванню у них ознак ЖСД і супроводжується різними...
- Open Access
- 30 March 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 18-27
Pre-pregnancy preparation of women with hypoandrogenism and female sexual dysfunction
The onset of pregnancy in the natural cycle is a task that requires the coordinated work of both central and peripheral levels of regulation of hypothalamic‑pituitary hormones. An analysis of the reproductive health of women with a menstrual cycle disorder against the background of hypoandrogenism indicates an unsatisfactory course of the early stages of the pregnancy process with the subsequent formation of infertility against the background of a reduced ovarian reserve. Hypolubrication is considered a clinical marker of hypoandrogenism in women of reproductive age. Objective — Optimization of pre‑pregnancy training in women with hypoandrogenism, menstrual cycle disorders and early pregnancy losses in the anamnesis. Materials and methods. A comprehensive clinical, laboratory and instrumental examination involved 90 women with menstrual cycle disorders and hypoandrogenism, from them 45 women received the proposed therapy (group Ia), and 45 patients traditional therapy (group IIa). The control group consisted of 30 healthy women at the stage of pre‑gravid examination. The age of women was 18 to 35 years. Hormonal reproductive background was determined on the 5 ‑ 7th day of the menstrual cycle in all examined women, as well as levels of thyroid‑stimulating hormone (TSH), thyroid peroxidase antibody, vitamin D, homocysteine. The proposed algorithm of pre‑gravid measures included: 1) optimization of thyroid gland function (after consultation with an endocrinologist); 2) restoration of pituitary‑ovarian relationships in case of functional central hypogonadism; 3) therapy aimed at optimizing the prolactin level (target value 12.5ng/ml); 4) reduction of homocysteine level (target level 5.6 mmol/l); 5) normalization of vitamin D level (norm is 75—125 nM/l, insufficiency defined as 50—75 nM/l, and deficiency <50 nM/l). The target control parameters included restoration of lubrication, ovulatory menstrual cycle, onset and progression of pregnancy. IBM SPSS Statistics version 25.0 software was used for statistical processing of the obtained data. The control periods of therapy were 3, 6 and 9 months. Results. In women with proposed treatment algorithm, therapy resulted in the recovery of vitamin D levels, starting from the 6th month of therapy, and complete normalization was recorded at the 9th month of treatment. This indicates the need for long‑term supplementation of vitamin D in women with hypoandrogenism. A decrease in the homocysteine levels was also noted on the 6th month of treatment, and its normalization after 9 months of treatment. Elevated homocysteine levels and vitamin D insufficiency/deficiency were observed throughout the follow‑up period in the conventional therapy group. In women with the proposed therapy, the levels of follicle‑stimulating hormone (FSH), TSH, luteinizing hormone (LH) and prolactin tend to normalize already from the 3rd month of therapy, while the highest positive increase was noted in the LH indicator on the 3rd‑6th month of treatment. Ovarian steroidogenesis approached the indicators of the control group after 6—9 months of therapy. Proandrogenic steroidogenesis began to increase on the 3rd month of therapy, reaching maximum on the 9th month. Unsatisfactory indicators of changes in free testosterone and dehydroepiandrosterone sulfate (DHEA‑C) were noted in women from the group of the traditional pre‑pregnancy preparation even after 9 months. The specified features of steroid support of the hormonal background of women’s reproductive health demonstrated the following: signs of female sexual dysfunction in the group with the proposed therapy completely disappeared after the 9th month of treatment, and in the group of traditional therapy they continued to bother 91.1% of women. At the end of the observation period, the regular menstrual cycle was gained in 40.0% of women with the proposed therapy and in 6.7% with the traditional one. Progressive pregnancies in the group with the proposed algorithm were achieved in 37.5% of women (successfully overcame the luteoplacental barrier), and in 8.8% in the group of the traditional approach (ended by early termination of pregnancy). Conclusions. The period of formation of the luteal phase insufficiency is the specific feature of the restoration of menstrual cycle fullness in women with hypoandrogenism, which requires additional therapy to ensure the conditions for a full‑fledged secretory endometrium transformation. The pregnancy process takes place in unfavorable conditions, which can lead to early pregnancy losses. The period of pre‑pregnancy measures in this group of patients should last at least 6—9 months. Traditional pre‑pregnancy preparation does not contribute to the restoration of the central mechanisms of menstrual cycle regulation in women with hypoandrogenism, nor does it contribute to the restoration of full‑fledged ovarian steroidogenesis, it is accompanied by anovulation and insufficiency of the luteal phase, early pregnancy losses. Symptoms of female sexual dysfunction do not disappear under the influence of traditional treatment.
- 30 March 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 18-27
Open AccessPre-pregnancy preparation of women with hypoandrogenism and female sexual dysfunction
The onset of pregnancy in the natural cycle is a task that requires the coordinated work of both central and peripheral levels of regulation of hypothalamic‑pituitary hormones. An analysis of the reproductive health of women with a menstrual cycle disorder against the background of hypoandrogenism indicates an unsatisfactory course of the early stages of the pregnancy process with the subsequent formation of infertility against the background of a reduced ovarian reserve. Hypolubrication is considered a clinical marker of hypoandrogenism in women of reproductive age. Objective — Optimization of pre‑pregnancy training in women with hypoandrogenism, menstrual cycle disorders and early pregnancy losses in the anamnesis. Materials and methods. A comprehensive clinical, laboratory and instrumental examination involved 90 women with menstrual cycle disorders and hypoandrogenism, from them 45 women received the proposed therapy (group Ia), and 45 patients traditional therapy (group IIa). The control group consisted of 30 healthy women at the stage of pre‑gravid examination. The age of women was 18 to 35 years. Hormonal reproductive background was determined on the 5 ‑ 7th day of the menstrual cycle in all examined women, as well as levels of thyroid‑stimulating hormone (TSH), thyroid peroxidase antibody, vitamin D, homocysteine. The proposed algorithm of pre‑gravid measures included: 1) optimization of thyroid gland function (after consultation with an endocrinologist); 2) restoration of pituitary‑ovarian relationships in case of functional central hypogonadism; 3) therapy aimed at optimizing the prolactin level (target value 12.5ng/ml); 4) reduction of homocysteine level (target level 5.6 mmol/l); 5) normalization of vitamin D level (norm is 75—125 nM/l, insufficiency defined as 50—75 nM/l, and deficiency <50 nM/l). The target control parameters included restoration of lubrication, ovulatory menstrual cycle, onset and progression of pregnancy. IBM SPSS Statistics version 25.0 software was used for statistical processing of the obtained data. The control periods of therapy were 3, 6 and 9 months. Results. In women with proposed treatment algorithm, therapy resulted in the recovery of vitamin D levels, starting from the 6th month of therapy, and complete normalization was recorded at the 9th month of treatment. This indicates the need for long‑term supplementation of vitamin D in women with hypoandrogenism. A decrease in the homocysteine levels was also noted on the 6th month of treatment, and its normalization after 9 months of treatment. Elevated homocysteine levels and vitamin D insufficiency/deficiency were observed throughout the follow‑up period in the conventional therapy group. In women with the proposed therapy, the levels of follicle‑stimulating hormone (FSH), TSH, luteinizing hormone (LH) and prolactin tend to normalize already from the 3rd month of therapy, while the highest positive increase was noted in the LH indicator on the 3rd‑6th month of treatment. Ovarian steroidogenesis approached the indicators of the control group after 6—9 months of therapy. Proandrogenic steroidogenesis began to increase on the 3rd month of therapy, reaching maximum on the 9th month. Unsatisfactory indicators of changes in free testosterone and dehydroepiandrosterone sulfate (DHEA‑C) were noted in women from the group of the traditional pre‑pregnancy preparation even after 9 months. The specified features of steroid support of the hormonal background of women’s reproductive health demonstrated the following: signs of female sexual dysfunction in the group with the proposed therapy completely disappeared after the 9th month of treatment, and in the group of traditional therapy they continued to bother 91.1% of women. At the end of the observation period, the regular menstrual cycle was gained in 40.0% of women with the proposed therapy and in 6.7% with the traditional one. Progressive pregnancies in the group with the proposed algorithm were achieved in 37.5% of women (successfully overcame the luteoplacental barrier), and in 8.8% in the group of the traditional approach (ended by early termination of pregnancy). Conclusions. The period of formation of the luteal phase insufficiency is the specific feature of the restoration of menstrual cycle fullness in women with hypoandrogenism, which requires additional therapy to ensure the conditions for a full‑fledged secretory endometrium transformation. The pregnancy process takes place in unfavorable conditions, which can lead to early pregnancy losses. The period of pre‑pregnancy measures in this group of patients should last at least 6—9 months. Traditional pre‑pregnancy preparation does not contribute to the restoration of the central mechanisms of menstrual cycle regulation in women with hypoandrogenism, nor does it contribute to the restoration of full‑fledged ovarian steroidogenesis, it is accompanied by anovulation and insufficiency of the luteal phase, early pregnancy losses. Symptoms of female sexual dysfunction do not disappear under the influence of traditional treatment.